Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257Ighovwerha Ofotokun, M. Adams, Lumine H Na et al.|Clinical Infectious Diseases|2015Cited by 82
Phase I/II Trial of the Anti-HIV Activity of Mifepristone in HIV-Infected Subjects ACTG 5200Michael F. Para, Barbara Brizz, Jeff Schouten et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2010Cited by 11
Effect of SARS-CoV-2 IgG Seroconversion After Convalescent Plasma Transfusion on Hospital Outcomes in COVID-19Sonal Pannu, Jeffrey C. Horowitz, Matthew C. Exline et al.|CHEST Critical Care|2024Cited by 1
Phase I/II Trial of the Anti-HIV Activity of Mifepristone in HIV-Infected Subjects ACTG 5200Yu Song, Barbara Brizz, Pablo Tebas et al.|UNC Libraries|2020Cited by 0
Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257Randi Y. Leavitt, Grace A. McComsey, Michael F. Para et al.|UNC Libraries|2020Cited by 0